Approximately 1,899 bottles of Valsartan and Valsartan with Hydrochlorothiazide (HCTZ) are being recalled because a carcinogen impurity was detected in the active ingredient used to manufacture these blood pressure medications. The recall involves various bottle sizes and strengths, including 80 mg, 160 mg, and 320 mg tablets distributed nationwide. Consumers using these medications should contact their doctor or pharmacist immediately, as the presence of this impurity may pose a long-term health risk. No specific injuries have been reported in this notice, but the firm initiated the recall due to deviations from manufacturing quality standards.
The medication contains an impurity classified as a carcinogen, which is a substance that could potentially cause cancer with long-term exposure. This impurity was found in the Active Pharmaceutical Ingredient (API) provided by overseas suppliers during the manufacturing process.
Contact healthcare provider and return product
If you or a family member were harmed by this recalled product, you may have legal rights. Consider consulting a consumer protection attorney to understand your options for compensation.
This is general information, not legal advice. Go Backs is not a law firm and does not provide legal services.
AI-Enhanced Content: The summary, action steps, and risk assessment on this page were generated by AI from official government recall data to improve readability. This is not legal or medical advice. Always refer to the official agency sources below for authoritative information.
Sources: FDA iRES · Raw API Response
openFDA Disclaimer: This recall information is sourced from the openFDA API. Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. Refer to the openFDA terms of service for more information.